Page 7 - Read Online

GENERAL INFORMATION

About the Journal
Cancer Drug Resistance (CDR), ISSN 2578-532X (Online), is a peer-reviewed online journal with print on demand compilation of
articles published. The journal’s full text is available online at www.oaepublish.com/cdr. The journal allows free access (Open Access)
to its contents and permits authors to self-archive final accepted version of the articles on any OAI-compliant institutional/subject-based
repository. The journal publishes research articles, reviews, case reports, commentaries and letters on pharmacological aspects of drug
resistance and its reversal, including drug design, drug delivery, drug distribution and cellular drug resistance. Molecular mechanisms
of drug resistance also cover the cellular pharmacology of drug resistance such as influx and efflux pumps (including the ABC pumps),
receptors and their ligands, cellular signaling pathways, drug activation and degradation (including Phase I and II metabolism),
drug sequestration, target modification and DNA repair. Drug classes to be covered include DNA targeted drugs and antihormones
as well as antibodies and protein kinase inhibitors. Both clinical and experimental aspects of drug resistance in cancer are included.

Cancer Drug Resistance (CDR) was founded with Professor Godefridus J. Peters as the Editor-in-Chief in March 2018. In a testament to
its growing prominence and scholarly impact, CDR has achieved several notable milestones in recent years. The journal’s recognition
journey began in March 2021 with its inclusion in the esteemed Scopus indexing. This was followed by another significant accolade
in May 2022, as CDR secured its place in the PubMed Central® (PMC) database, further amplifying its reach and accessibility
to the global research community. The year 2023 marked a series of remarkable achievements for CDR, with Scopus bestowing a
CiteScore of 5.5, which subsequently surged to an impressive 6.3 as per the latest CiteScoreTracker update as of December 5, 2023.
Furthermore, June 2023 emerged as a landmark month for CDR, as it achieved its first Impact Factor of 3.7, a recognition conferred by
Clarivate Analytics in the esteemed Journal Citation Report (JCR). These milestones not only underscore the journal’s commitment
to advancing the field of cancer drug resistance but also reflect its growing influence and stature in the scientific community.

Information for Authors
Manuscripts must be prepared in accordance with Author Instructions.
Please check www.cdrjournal.com/pages/view/author_instructions for details.
All manuscripts must be submitted online at www.oaemesas.com/cdr/.
Copyright
The entire contents of the CDR are protected under international copyrights. The journal, however, grants to all users a free, irrevocable,
worldwide, perpetual right of access to, and a license to copy, use, distribute, perform and display the work publicly and to make and
distribute derivative works in any digital medium for any reasonable purpose, subject to proper attribution of authorship and ownership
of the rights. The journal also grants the right to make small numbers of printed copies for their personal use under the Creative
Commons Attribution 4.0 International License.
Copyright is reserved by © The Author(s) 2023.
Permissions
For information on how to request permissions to reproduce articles/information from this journal, please visit www.oaepublish.
com/cdr
Disclaimer
The information and opinions presented in the journal reflect the views of the authors and not of the journal or its Editorial Board or the
Publisher. Publication does not constitute endorsement by the journal. Neither the CDR nor its publishers nor anyone else involved in
creating, producing or delivering the CDR or the materials contained therein, assumes any liability or responsibility for the accuracy,
completeness, or usefulness of any information provided in the CDR, nor shall they be liable for any direct, indirect, incidental, special,
consequential or punitive damages arising out of the use of the CDR. The CDR, nor its publishers, nor any other party involved in the
preparation of material contained in the CDR represents or warrants that the information contained herein is in every respect accurate
or complete, and they are not responsible for any errors or omissions or for the results obtained from the use of such material. Readers
are encouraged to confirm the information contained herein with other sources.

Published by Contacts
OAE Publishing Inc. E-mail: editorial@cdrjournal.com
245 E Main Street ste 107, Alhambra, CA 91801, USA Website: www.oaepublish.com/cdr
Website: www.oaepublish.com/cdr

Cancer Drug Resistance IV